Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [ 64 Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron emission t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2021-11, Vol.12, p.790405-790405
Main Authors: Jensen, Jacob K, Zobel, Emilie H, von Scholten, Bernt J, Rotbain Curovic, Viktor, Hansen, Tine W, Rossing, Peter, Kjaer, Andreas, Ripa, Rasmus S
Format: Article
Language:English
Subjects:
Aged
atherosclerosis
Cohort Studies
coronary arteries
Coronary Vessels - diagnostic imaging
Coronary Vessels - drug effects
Coronary Vessels - metabolism
Diabetes Mellitus, Type 2 - diagnostic imaging
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Double-Blind Method
Drug Administration Schedule
Endocrinology
Female
Follow-Up Studies
Humans
Hypoglycemic Agents - administration & dosage
inflammation
Liraglutide - administration & dosage
Male
Middle Aged
molecular imaging
PET
Positron Emission Tomography Computed Tomography - methods
Positron-Emission Tomography - methods
Radionuclide Imaging - methods
Treatment Outcome
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron emission tomography (PET) with a radioactive tracer targeting activated macrophages in the vessel-wall. Thirty randomly selected participants with type 2 diabetes from the placebo-controlled trial LIRAFLAME were enrolled in this sub-study. Participants were, prior to enrollment in this sub-study, randomized to either treatment with daily liraglutide (n=15) or placebo (n=15). Both groups underwent a combined [ Cu]Cu-DOTATATE positron emission tomography and computed tomography scan of the heart at baseline and after 26 weeks of treatment. Coronary artery uptake of [ Cu]Cu-DOTATATE were measured as maximum standardized uptake values (SUV ); and means of the maximum values (mSUV ), both values were calculated at the level of each participant and each individual coronary-segment. SUV and mSUV values decreased significantly in the liraglutide group both at the participant level (SUV : p=0.013; mSUV : p=0.004) and at the coronary-segment level (SUV : p=0.001; mSUV : p
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.790405